NADROPARIN
Iatrogenic Disease
Rijnstate Hospitalother_biologicalPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Iatrogenic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
AUTOLOGOUS CONDITIONED PLASMA Star Spine and Sport | Phase 4 | BB |
Velpatasvir Alexandria University | Phase 4 | BB |
Sofosbuvir Alexandria University | Phase 4 | BB |
NEPENTHE Tiva Group | Phase 4 | BB |
Paliperidone Consorcio Centro de Investigación Biomédica en Red (CIBER) | Phase 4 | BB |
View all 36 →
Same molecule, other indications
NADROPARIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →